These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2378791)

  • 1. Ketanserin pharmacokinetics in patients with renal failure.
    Barendregt JN; Van Peer A; Van Der Hoeven JG; Van Oene JC; Tjandra YI
    Br J Clin Pharmacol; 1990 Jun; 29(6):715-23. PubMed ID: 2378791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ketanserin in patients with essential hypertension.
    Persson B; Pettersson A; Hedner T
    Eur J Clin Pharmacol; 1987; 32(3):259-65. PubMed ID: 3595699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of ketanserin in chronic hemodialysed patients.
    Zazgornik J; Scholz N; Kuska J; Minar E
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):674-6. PubMed ID: 3818146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma protein binding of ketanserin and its distribution in blood.
    Meuldermans W; Van Houdt J; Mostmans E; Knaeps F; Verluyten W; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):794-800. PubMed ID: 3178920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.
    Heykants J; Van Peer A; Woestenborghs R; Gould S; Mills J
    Eur J Clin Pharmacol; 1986; 31(3):343-50. PubMed ID: 3792432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of ketanserin.
    Persson B; Heykants J; Hedner T
    Clin Pharmacokinet; 1991 Apr; 20(4):263-79. PubMed ID: 2036747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
    Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol.
    Van Peer A; Woestenborghs R; Embrechts L; Heykants J
    Eur J Clin Pharmacol; 1986; 31(3):339-42. PubMed ID: 3792431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ketanserin in man.
    Reimann IW; Okonkwo PO; Klotz U
    Eur J Clin Pharmacol; 1983; 25(1):73-6. PubMed ID: 6617728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.
    Williams FM; Leeser JE; Rawlins MD
    Br J Clin Pharmacol; 1986 Sep; 22(3):301-8. PubMed ID: 3768242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects.
    Waller PC; Tucker GT; Ramsay LE
    Eur J Clin Pharmacol; 1987; 33(4):423-6. PubMed ID: 3443148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ketanserin in patients with cirrhosis.
    Lebrec D; Hadengue A; Gaudin C; Levron JC; Fraitag B; Berthelot P; Benhamou JP
    Clin Pharmacokinet; 1990 Aug; 19(2):160-6. PubMed ID: 2379381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis.
    Fillastre JP; Taburet AM; Fialaire A; Etienne I; Bidault R; Singlas E
    Drugs Exp Clin Res; 1993; 19(1):25-32. PubMed ID: 8223137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism and excretion of ketanserin in man after oral administration.
    Meuldermans W; Hendrickx J; Woestenborghs R; Van Peer A; Lauwers W; De Cree J; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):789-94. PubMed ID: 3178919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency.
    Rovei V; Campistron G; Dueymes JM; Ego D; Conte JJ; Houin G
    Eur J Clin Pharmacol; 1987; 33(3):303-10. PubMed ID: 3691618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of the in vitro and in vivo pharmacological profile of the major metabolites of ketanserin in the rat.
    Heykants J; Michiels M; Woestenborghs R; Awouters F; Leysen JE; Schuurkes J; Van Nueten JM
    Arzneimittelforschung; 1988 Jun; 38(6):785-8. PubMed ID: 3178918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.
    Thompson-Culkin K; Zussman B; Miller AK; Freed MI
    J Int Med Res; 2002; 30(4):391-9. PubMed ID: 12235921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic renal failure on the pharmacokinetics of ruboxistaurin and its active metabolite 338522.
    Wise S; Yuen E; Chan C; Poo YK; Teng L; Lau T; Voelker J
    Clin Pharmacokinet; 2006; 45(3):297-303. PubMed ID: 16509761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.
    Flouvat B; Decourt S; Aubert P; Potaux L; Domart M; Goupil A; Baglin A
    Br J Clin Pharmacol; 1980 Apr; 9(4):379-85. PubMed ID: 7378254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.